Send to

Choose Destination
Endokrynol Pol. 2006 Jul-Aug;57(4):438-44.

[BRAF initiating mutations in the papillary thyroid carcinoma].

[Article in Polish]

Author information

Department of Nuclear Medicine and Endocrine Oncology MSC Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice.


Among genetic alterations most important for the initiation of papillary thyroid carcinoma (PTC) is mutation T1799A in the BRAF gene which is the most frequent event (54.5%) in this type of thyroid cancer. It is seen in all stages, from microcarcinoma through clinically overt disease to anaplastic cancer. It has been shown that BRAF mutation is correlated with PTC histotype. It is identified most frequently in classical PTC and in tall cell variant. Moreover, BRAF mutation is described more often in older patients, whereas in young patients RET/PTC rearrangements dominate. In PTC cases with BRAF mutation V600E the prognosis is poorer, with more cancer invasiveness, metastasis and recurrence. The presence of BRAF mutation is related to the specific gene expression signature, different than in cancer cases showing RET/PTC rearrangement or no known initiating mutation.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center